Literature DB >> 12942713

Mycobacteria tuberculosis peritonitis associated with etanercept therapy.

A M Manadan, J A Block, W Sequeira.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12942713

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN： 0392-856X            Impact factor:   4.473


× No keyword cloud information.
  9 in total

Review 1.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

2.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

4.  Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab.

Authors:  Alfonso Gutiérrez-Macías; Eva Lizarralde-Palacios; Pedro Martínez-Odriozola; Felipe Miguel-de la Villa
Journal:  Clin Rheumatol       Date:  2006-01-11       Impact factor: 2.980

Review 5.  Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 6.  Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 7.  Hereditary auto-inflammatory disorders and biologics.

Authors:  Leigh D Church; Sarah M Churchman; Philip N Hawkins; Michael F McDermott
Journal:  Springer Semin Immunopathol       Date:  2006-05-04

Review 8.  Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.228

9.  Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement.

Authors:  Gerd Horneff; Sigrid Fitter; Ivan Foeldvari; Kirsten Minden; Jasmin Kuemmerle-Deschner; Nicolay Tzaribacev; Angelika Thon; Michael Borte; Gerd Ganser; Rolf Trauzeddel; Hans-Iko Huppertz
Journal:  Arthritis Res Ther       Date:  2012-10-24       Impact factor: 5.156
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.